Pharmacokinetics of lopinavir in HIV-infected adults receiving rifampin with adjusted doses of lopinavir-ritonavir tablets

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 7, 2011, Pages 3195-3200

  Decloedt, Eric H ^a   McIlleron, Helen ^a   Smith, Peter ^a   Merry, Concepta ^b   Orrell, Catherine ^c   Maartens, Gary ^a  

^a UNIVERSITY OF CAPE TOWN   (South Africa)

^b ST JAMES S HOSPITAL   (Ireland)

^c UNIVERSITY OF CAPE TOWN   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR PLUS RITONAVIR; RIFAMPICIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG BLOOD LEVEL; DRUG DOSE INCREASE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; HYPERTRANSAMINASEMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PR INTERVAL; PRIORITY JOURNAL; SIDE EFFECT; TABLET; UNSPECIFIED SIDE EFFECT;

ADULT; ANTI-HIV AGENTS; FEMALE; HIV INFECTIONS; HUMANS; MALE; PYRIMIDINONES; RIFAMPIN; RITONAVIR; TABLETS;

EID: 79959215519     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01598-10     Document Type: Article

References (22)

1. Ananworanich, J., et al. 2005. Pharmacokinetics and 24-week efficacy/safety of dual boosted saquinavir/lopinavir/ritonavir in nucleoside-pretreated children. Pediatr. Infect. Dis. J. 24:874-879.
2. Centers for Disease Control and Prevention. 2007. Managing drug interactions in the treatment of HIV-related tuberculosis. http://www.cdc.gov/ tb/publications/guidelines/HIV-AIDS.htm. Accessed 13 August 2010.
3. Desta, Z., N. V. Soukhova, and D. A. Flockhart. 2001. Inhibition of cytochrome P450 (CYP450) isoforms by isoniazid: potent inhibition of CYP2C19 and CYP3A. Antimicrob. Agents Chemother. 45:382-392.
4. Division of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health. 2004. Division of AIDS table for grading the severity of adult and pediatric adverse events. http://www.ucdmc.ucdavis.edu/ clinicaltrials/documents/DAIDS-AE-GradingTable-FinalDec2004.pdf. Accessed 13 August 2010.
5. Gordin, F. M., et al. 2004. Hepatotoxicity of rifampin and pyrazinamide in the treatment of latent tuberculosis infection in HIV-infected persons: is it different than in HIV-uninfected persons? Clin. Infect. Dis. 39:561-565.
6. Grange, S., M. Schutz, C. Schmitt, M. Riek, and E. Gaudeul-Ehrhart. 2005. Unexpected hepatotoxicity observed in a healthy volunteer study on the effects of multiple dose rifampicin on the steady-state pharmacokinetics of ritonavir-boosted sequinavir and vice versa, abstr. 35. Sixth Int. Workshop Clin. Pharmacol. HIV Ther., Montreal, Quebec, Canada, 28 to 30 April 2005.
7. Haas, D. W., et al. 2009. Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir. J. Acquir. Immune Defic. Syndr. 50:290-293.
8. Hsu, A., et al. 1997. Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrob. Agents Chemother. 41:898-905.
9. Jasmer, R. M., et al. 2002. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a multicenter clinical trial. Ann. Intern. Med. 137:640-647.
10. Justesen, U. S., and C. Pedersen. 2002. Diurnal variation of plasma protease inhibitor concentrations. AIDS 16:2487-2489. (Pubitemid 35471700)
11. La Porte, C. J. L., et al. 2006. Updated guideline to perform therapeutic drug monitoring for antiviral agents. Rev. Antivir. Ther. 3:4-14.
12. La Porte, C. J., et al. 2004. Pharmacokinetics of adjusted-dose lopinavirritonavir combined with rifampin in healthy volunteers. Antimicrob. Agents Chemother. 48:1553-1560.
13. Lee, W. M. 2003. Drug-induced hepatotoxicity. N. Engl. J. Med. 349:474-485.
14. Losso, M. H., L. D. Lourtau, J. J. Toibaro, C. Saenz, and C. Gonzalez. 2004. The use of saquinavir/ritonavir 1000/100 mg twice daily in patients with tuberculosis receiving rifampin. Antivir. Ther. 9:1031-1033.
15. Niemi, M., J. T. Backman, M. F. Fromm, P. J. Neuvonen, and K. T. Kivisto. 2003. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin. Pharmacokinet. 42:819-850.
16. Nijland, H. M., et al. 2008. High incidence of adverse events in healthy volunteers receiving rifampicin and adjusted doses of lopinavir/ritonavir tablets. AIDS 22:931-935. (Pubitemid 351652243)
17. Ren, Y., et al. 2008. Effect of rifampicin on lopinavir pharmacokinetics in HIV-infected children with tuberculosis. J. Acquir. Immune Defic. Syndr. 47:566-569.
18. Ribera, E., et al. 2007. Pharmacokinetic interaction between rifampicin and the once-daily combination of saquinavir and low-dose ritonavir in HIV-infected patients with tuberculosis. J. Antimicrob. Chemother. 59:690-697.
19. Sekar, V., R. Ryan, D. Schaible, A. Mazikewich, and J. Mrus. 2008. Pharmacokinetic profile of darunavir co-administered with low-dose ritonavir in treatment-experienced women and men with HIV infection: 4-week analysis in a substudy of the GRACE (gender, race and clinical experience) study, abstr. O16, p. 46. Abstr. Ninth Int. Workshop Clin. Pharmacol. HIV Ther., New Orleans, LA, 7 to 9 April 2008.
20. Tortajada, C., et al. 2005. Is the combination of pyrazinamide plus rifampicin safe for treating latent tuberculosis infection in persons not infected by the human immunodeficiency virus? Int. J. Tuberc. Lung Dis. 9:276-281.
21. Umeh, O. C., et al. 13 January 2011. Sex differences in lopinavir and ritonavir pharmacokinetics among HIV-infected women and men. J. Clin. Pharmacol. [Epub ahead of print.] doi:10.1177/0091270010388650.
22. Zhou, S., et al. 2004. Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4. Curr. Drug Metab. 5:415-442.